Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY 2433334 versus apixaban in atrial fibrillation
NL-OMON49562Phase 2Active, not recruiting
- Sponsor
- Bayer
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of asundexian and apixaban in Atrial fibrillation (AFib) (3 arms), sponsored by Bayer. Primary endpoint: Primary safety endpoint. Started Jun 2020; status: active, not recruiting.
02
Drugs
asundexianapixaban
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NL-OMON49562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49562.